PROPANC BIOPHARMA, INC.: 10-Q filed 2017-02-14
What PROPANC BIOPHARMA, INC. reported in its quarterly report filed 2017-02-14 (fiscal Q2 2017): 23 published measures, 64 facts as tagged in accession 0001144204-17-008493.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-02-14
- Fiscal period
- fiscal Q2 2017
- Accession
- 0001144204-17-008493 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PROPANC BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 135,838 | USD | |
| At 2016-06-30 | 379,142 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -3,840,652 | USD | |
| At 2016-06-30 | -2,565,293 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -3,760,913 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -4,862,882 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,562,067 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,400,961 | USD | 184 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 0 | USD | 184 |
| 2015-07-01 to 2015-12-31 | 676 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -35,238,905 | USD | |
| At 2016-06-30 | -30,376,023 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 0 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 0 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -72,000 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -72,000 | USD | 184 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 11,141 | USD | |
| At 2016-06-30 | 12,527 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -1,909,086 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -3,083,383 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -1,143,821 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -2,151,212 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 122,538 | USD | |
| At 2016-06-30 | 362,767 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 1,255,627 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 1,727,014 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 1,155,645 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 1,574,289 | USD | 184 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 3,976,490 | USD | |
| At 2016-06-30 | 2,944,435 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 441,769 | USD | |
| At 2016-06-30 | 250,403 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 1,909,086 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 3,083,383 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 1,143,821 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 2,151,212 | USD | 184 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 167,202 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 328,399 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 142,803 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 296,277 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 867,281,734 | shares | |
| At 2016-06-30 | 728,616,312 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 30,137,809 | USD | |
| At 2016-06-30 | 26,945,849 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 388,162 | USD | |
| At 2016-06-30 | 131,264 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 69,252 | USD | |
| At 2016-06-30 | 210,122 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -3,279,196 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -4,605,984 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,708,618 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,289,082 | USD | 184 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 1,735,893 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 2,740,396 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 996,129 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 1,845,108 | USD | 184 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 1,091 | USD | 184 |
| 2015-07-01 to 2015-12-31 | 340 | USD | 184 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -1,851,827 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -1,779,499 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -2,490,246 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -2,321,749 | USD | 184 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 85,790 | USD | 184 |
| 2015-07-01 to 2015-12-31 | -118,305 | USD | 184 |
Inspect the source
- Entity
- PROPANC BIOPHARMA, INC. / CIK 0001517681
- Captured
- 2026-09-20T09:14:07.933Z
- SEC response SHA-256
4f6eac6bf72e7f988a9a94ea85589b445974414449c4b417540ed20477181487
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001517681.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))